Biotechnology company
Appears in 1 story
Markets Lumvoa, approved June 2026; developing subcutaneous alternative
The FDA approved Roche's Enspryng for thyroid eye disease on October 15, the first and only at-home subcutaneous treatment for the condition. Patients or caregivers inject the drug with a prefilled syringe or pen after a healthcare provider's training — no infusion clinic visits.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
